ESC 365 - Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study

Open Access

Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study

Session: ePosters in chronic heart failure - pharmacotherapy (2)

Topic: Pharmacotherapy

Speaker: Doctor E. Haakansson (Umea, SE)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Erik Haakansson

Umea University Hospital, Umea (Sweden)

0 follower

5 more presentations in this session

Which treatment attributes do patients with transthyretin amyloid cardiomyopathy value most?

Speaker: Ms A. Carr (Hagersville, CA)

Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.

Speaker: Doctor A. Michel (Basel, CH)

The care-gap for women living with heart failure

Speaker: Doctor O. Graham (Craigavon, GB)

Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study

Speaker: Doctor C. Gregorio (Lisbon, PT)

Ambulatory blood pressure monitoring reveals true significant hypotension in stable HF patients; Is this an overlooked issue?

Speaker: Doctor G. Bruno (Dublin, IE)

Access the full session

ePosters in chronic heart failure - pharmacotherapy (2)

Speakers: Doctor E. Haakansson, Ms A. Carr, Doctor A. Michel, Doctor O. Graham, Doctor C. Gregorio...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources